• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    1/26/24 4:40:02 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    Abbreviated New Drug Application (ANDA): 077334
    Company: AMPHASTAR PHARMS INC
    • Email

    Products on ANDA 077334

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription AB No No

    Approval Date(s) and History, Letters, Labels, Reviews for ANDA 077334

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    11/28/2017 ORIG-1 Approval

    Label is not available on this site.

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    01/25/2024 SUPPL-5 Labeling-Package Insert, Labeling-Container/Carton Labels

    Label is not available on this site.

    Therapeutic Equivalents for ANDA 077334

    MEDROXYPROGESTERONE ACETATE

    INJECTABLE;INJECTION; 150MG/ML
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    DEPO-PROVERA MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription Yes AB 020246 PFIZER
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 215397 AMNEAL
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 077235 AMPHASTAR PHARMS INC
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 077334 AMPHASTAR PHARMS INC
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 212824 EUGIA PHARMA
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 212844 EUGIA PHARMA
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 076553 MEITHEAL
    MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE 150MG/ML INJECTABLE;INJECTION Prescription No AB 210227 MYLAN LABS LTD
    Get the next $AMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    7/29/2022$44.00Overweight
    CapitalOne
    More analyst ratings

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

      1/26/24 4:40:02 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

      12/27/23 4:38:39 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

      6/30/23 9:33:25 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    SEC Filings

    See more
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      6/3/25 8:46:19 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

      10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/8/25 4:24:18 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/7/25 4:23:10 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amphastar Pharmaceuticals downgraded by Analyst with a new price target

      Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

      5/12/25 8:19:14 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

      2/4/25 6:58:07 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amphastar Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Amphastar Pharmaceuticals with a rating of Equal Weight and set a new price target of $55.00

      11/22/24 7:19:52 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. exercised 200,000 shares at a strike of $13.03, increasing direct ownership by 8% to 2,847,659 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/16/25 5:19:35 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Howard was granted 5,122 shares and covered exercise/tax liability with 923 shares, increasing direct ownership by 3% to 151,976 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 8:04:41 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deflin Gayle was granted 5,122 shares, increasing direct ownership by 88% to 10,914 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 7:45:15 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care